Baidu
map

J Bone Miner Metab:洛索洛芬可抑制唑来膦酸诱导的急性期反应

2020-12-09 网络 网络

唑来膦酸输液用于治疗骨质疏松症,但是许多日本患者会出现急性期反应(APRs)。在这项多中心、随机、开放标签、平行组研究中,研究人员评估了日本最常用的非甾体抗炎药洛索洛芬在降低唑来膦酸引起的APRs发生

唑来膦酸输液用于治疗骨质疏松症,但是许多日本患者会出现急性期反应(APRs)。在这项多中心、随机、开放标签、平行组研究中,研究人员评估了日本最常用的非甾体抗炎药洛索洛芬在降低唑来膦酸引起的APRs发生率和体温方面的疗效,并调查了该人群APRs的风险/保护因素,研究结果已在线发表于J Bone Miner Metab。

研究纳入年龄≥60岁的原发性骨质疏松症患者(n = 368),随机分配到唑来膦酸加洛索洛芬组(ZOL + LOX)或单独使用唑来膦酸组(ZOL)。所有患者在第1天接受5mg唑来膦酸输注,ZOL + LOX组患者在第1天和第2天还分别接受120mg和180mg口服洛索洛芬。在7天的观察期内,记录不良事件和体温。

 

结果显示,ZOL+LOX组和ZOL组的APRs发生率分别为34.4%(64/186例)和47.8%(87/182例)(P=0.0109)。两组患者体温升高(≥1℃和≥37.5℃)的比例相似(P = 0.1186)。过去双膦酸盐使用者的APRs发生率明显低于未接受治疗的患者(OR 0.444,95%置信区间0.285-0.692,P = 0.0003)。

综上所述,该研究结果表明,洛索洛芬可抑制唑来膦酸诱导的APRs。已知的风险/保护因素,包括先前的骨质疏松症治疗,适用于日本患者。

 

原始出处:

 

Nobukazu Okimoto, Akinori Sakai, et al., Efficacy of non-steroidal anti-inflammatory drugs on zoledronic acid-induced acute-phase reactions: randomized, open-label, Japanese OZ study. J Bone Miner Metab. 2020 Mar;38(2):230-239. doi: 10.1007/s00774-019-01050-8.  

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1678275, encodeId=0fc716e827536, content=<a href='/topic/show?id=12025231333' target=_blank style='color:#2F92EE;'>#急性期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52313, encryptionId=12025231333, topicName=急性期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b8027680692, createdName=feifers, createdTime=Wed May 19 03:26:44 CST 2021, time=2021-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896785, encodeId=80e01896e85cc, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sat May 22 06:26:44 CST 2021, time=2021-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1888249, encodeId=8f10188824927, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Tue Jun 01 22:26:44 CST 2021, time=2021-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915217, encodeId=e5b4191521e2b, content=<a href='/topic/show?id=05343619cf' target=_blank style='color:#2F92EE;'>#Bone#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3619, encryptionId=05343619cf, topicName=Bone)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Fri Jul 02 09:26:44 CST 2021, time=2021-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=909122, encodeId=936c90912245, content=这都能发出来,受教了, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200802/2d1be4b00f2042fdb7133156db033753/68b000cd6c2e409688928b278fd0eebb.jpg, createdBy=4e205263076, createdName=Super骨科赵, createdTime=Fri Dec 18 14:50:17 CST 2020, time=2020-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379696, encodeId=913613e9696be, content=<a href='/topic/show?id=6d8340012ff' target=_blank style='color:#2F92EE;'>#唑来膦酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40012, encryptionId=6d8340012ff, topicName=唑来膦酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3307462, createdName=风铃821, createdTime=Fri Dec 11 14:26:44 CST 2020, time=2020-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=906748, encodeId=34b3906e4882, content=洛索洛芬可抑制唑来膦酸诱导的急性期反应, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210325/2d9c955949df4b349a439f1a6773499e/b39f4845e869489d95bc545c79cf60fa.jpg, createdBy=303f5433779, createdName=Oranhyg, createdTime=Thu Dec 10 16:37:09 CST 2020, time=2020-12-10, status=1, ipAttribution=)]
    2021-05-19 feifers
  2. [GetPortalCommentsPageByObjectIdResponse(id=1678275, encodeId=0fc716e827536, content=<a href='/topic/show?id=12025231333' target=_blank style='color:#2F92EE;'>#急性期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52313, encryptionId=12025231333, topicName=急性期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b8027680692, createdName=feifers, createdTime=Wed May 19 03:26:44 CST 2021, time=2021-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896785, encodeId=80e01896e85cc, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sat May 22 06:26:44 CST 2021, time=2021-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1888249, encodeId=8f10188824927, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Tue Jun 01 22:26:44 CST 2021, time=2021-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915217, encodeId=e5b4191521e2b, content=<a href='/topic/show?id=05343619cf' target=_blank style='color:#2F92EE;'>#Bone#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3619, encryptionId=05343619cf, topicName=Bone)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Fri Jul 02 09:26:44 CST 2021, time=2021-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=909122, encodeId=936c90912245, content=这都能发出来,受教了, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200802/2d1be4b00f2042fdb7133156db033753/68b000cd6c2e409688928b278fd0eebb.jpg, createdBy=4e205263076, createdName=Super骨科赵, createdTime=Fri Dec 18 14:50:17 CST 2020, time=2020-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379696, encodeId=913613e9696be, content=<a href='/topic/show?id=6d8340012ff' target=_blank style='color:#2F92EE;'>#唑来膦酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40012, encryptionId=6d8340012ff, topicName=唑来膦酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3307462, createdName=风铃821, createdTime=Fri Dec 11 14:26:44 CST 2020, time=2020-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=906748, encodeId=34b3906e4882, content=洛索洛芬可抑制唑来膦酸诱导的急性期反应, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210325/2d9c955949df4b349a439f1a6773499e/b39f4845e869489d95bc545c79cf60fa.jpg, createdBy=303f5433779, createdName=Oranhyg, createdTime=Thu Dec 10 16:37:09 CST 2020, time=2020-12-10, status=1, ipAttribution=)]
    2021-05-22 一闲
  3. [GetPortalCommentsPageByObjectIdResponse(id=1678275, encodeId=0fc716e827536, content=<a href='/topic/show?id=12025231333' target=_blank style='color:#2F92EE;'>#急性期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52313, encryptionId=12025231333, topicName=急性期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b8027680692, createdName=feifers, createdTime=Wed May 19 03:26:44 CST 2021, time=2021-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896785, encodeId=80e01896e85cc, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sat May 22 06:26:44 CST 2021, time=2021-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1888249, encodeId=8f10188824927, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Tue Jun 01 22:26:44 CST 2021, time=2021-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915217, encodeId=e5b4191521e2b, content=<a href='/topic/show?id=05343619cf' target=_blank style='color:#2F92EE;'>#Bone#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3619, encryptionId=05343619cf, topicName=Bone)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Fri Jul 02 09:26:44 CST 2021, time=2021-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=909122, encodeId=936c90912245, content=这都能发出来,受教了, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200802/2d1be4b00f2042fdb7133156db033753/68b000cd6c2e409688928b278fd0eebb.jpg, createdBy=4e205263076, createdName=Super骨科赵, createdTime=Fri Dec 18 14:50:17 CST 2020, time=2020-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379696, encodeId=913613e9696be, content=<a href='/topic/show?id=6d8340012ff' target=_blank style='color:#2F92EE;'>#唑来膦酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40012, encryptionId=6d8340012ff, topicName=唑来膦酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3307462, createdName=风铃821, createdTime=Fri Dec 11 14:26:44 CST 2020, time=2020-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=906748, encodeId=34b3906e4882, content=洛索洛芬可抑制唑来膦酸诱导的急性期反应, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210325/2d9c955949df4b349a439f1a6773499e/b39f4845e869489d95bc545c79cf60fa.jpg, createdBy=303f5433779, createdName=Oranhyg, createdTime=Thu Dec 10 16:37:09 CST 2020, time=2020-12-10, status=1, ipAttribution=)]
    2021-06-01 guojianrong
  4. [GetPortalCommentsPageByObjectIdResponse(id=1678275, encodeId=0fc716e827536, content=<a href='/topic/show?id=12025231333' target=_blank style='color:#2F92EE;'>#急性期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52313, encryptionId=12025231333, topicName=急性期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b8027680692, createdName=feifers, createdTime=Wed May 19 03:26:44 CST 2021, time=2021-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896785, encodeId=80e01896e85cc, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sat May 22 06:26:44 CST 2021, time=2021-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1888249, encodeId=8f10188824927, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Tue Jun 01 22:26:44 CST 2021, time=2021-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915217, encodeId=e5b4191521e2b, content=<a href='/topic/show?id=05343619cf' target=_blank style='color:#2F92EE;'>#Bone#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3619, encryptionId=05343619cf, topicName=Bone)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Fri Jul 02 09:26:44 CST 2021, time=2021-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=909122, encodeId=936c90912245, content=这都能发出来,受教了, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200802/2d1be4b00f2042fdb7133156db033753/68b000cd6c2e409688928b278fd0eebb.jpg, createdBy=4e205263076, createdName=Super骨科赵, createdTime=Fri Dec 18 14:50:17 CST 2020, time=2020-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379696, encodeId=913613e9696be, content=<a href='/topic/show?id=6d8340012ff' target=_blank style='color:#2F92EE;'>#唑来膦酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40012, encryptionId=6d8340012ff, topicName=唑来膦酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3307462, createdName=风铃821, createdTime=Fri Dec 11 14:26:44 CST 2020, time=2020-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=906748, encodeId=34b3906e4882, content=洛索洛芬可抑制唑来膦酸诱导的急性期反应, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210325/2d9c955949df4b349a439f1a6773499e/b39f4845e869489d95bc545c79cf60fa.jpg, createdBy=303f5433779, createdName=Oranhyg, createdTime=Thu Dec 10 16:37:09 CST 2020, time=2020-12-10, status=1, ipAttribution=)]
    2021-07-02 apoenzyme
  5. [GetPortalCommentsPageByObjectIdResponse(id=1678275, encodeId=0fc716e827536, content=<a href='/topic/show?id=12025231333' target=_blank style='color:#2F92EE;'>#急性期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52313, encryptionId=12025231333, topicName=急性期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b8027680692, createdName=feifers, createdTime=Wed May 19 03:26:44 CST 2021, time=2021-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896785, encodeId=80e01896e85cc, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sat May 22 06:26:44 CST 2021, time=2021-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1888249, encodeId=8f10188824927, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Tue Jun 01 22:26:44 CST 2021, time=2021-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915217, encodeId=e5b4191521e2b, content=<a href='/topic/show?id=05343619cf' target=_blank style='color:#2F92EE;'>#Bone#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3619, encryptionId=05343619cf, topicName=Bone)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Fri Jul 02 09:26:44 CST 2021, time=2021-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=909122, encodeId=936c90912245, content=这都能发出来,受教了, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200802/2d1be4b00f2042fdb7133156db033753/68b000cd6c2e409688928b278fd0eebb.jpg, createdBy=4e205263076, createdName=Super骨科赵, createdTime=Fri Dec 18 14:50:17 CST 2020, time=2020-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379696, encodeId=913613e9696be, content=<a href='/topic/show?id=6d8340012ff' target=_blank style='color:#2F92EE;'>#唑来膦酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40012, encryptionId=6d8340012ff, topicName=唑来膦酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3307462, createdName=风铃821, createdTime=Fri Dec 11 14:26:44 CST 2020, time=2020-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=906748, encodeId=34b3906e4882, content=洛索洛芬可抑制唑来膦酸诱导的急性期反应, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210325/2d9c955949df4b349a439f1a6773499e/b39f4845e869489d95bc545c79cf60fa.jpg, createdBy=303f5433779, createdName=Oranhyg, createdTime=Thu Dec 10 16:37:09 CST 2020, time=2020-12-10, status=1, ipAttribution=)]
    2020-12-18 Super骨科赵

    这都能发出来,受教了

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1678275, encodeId=0fc716e827536, content=<a href='/topic/show?id=12025231333' target=_blank style='color:#2F92EE;'>#急性期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52313, encryptionId=12025231333, topicName=急性期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b8027680692, createdName=feifers, createdTime=Wed May 19 03:26:44 CST 2021, time=2021-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896785, encodeId=80e01896e85cc, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sat May 22 06:26:44 CST 2021, time=2021-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1888249, encodeId=8f10188824927, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Tue Jun 01 22:26:44 CST 2021, time=2021-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915217, encodeId=e5b4191521e2b, content=<a href='/topic/show?id=05343619cf' target=_blank style='color:#2F92EE;'>#Bone#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3619, encryptionId=05343619cf, topicName=Bone)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Fri Jul 02 09:26:44 CST 2021, time=2021-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=909122, encodeId=936c90912245, content=这都能发出来,受教了, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200802/2d1be4b00f2042fdb7133156db033753/68b000cd6c2e409688928b278fd0eebb.jpg, createdBy=4e205263076, createdName=Super骨科赵, createdTime=Fri Dec 18 14:50:17 CST 2020, time=2020-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379696, encodeId=913613e9696be, content=<a href='/topic/show?id=6d8340012ff' target=_blank style='color:#2F92EE;'>#唑来膦酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40012, encryptionId=6d8340012ff, topicName=唑来膦酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3307462, createdName=风铃821, createdTime=Fri Dec 11 14:26:44 CST 2020, time=2020-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=906748, encodeId=34b3906e4882, content=洛索洛芬可抑制唑来膦酸诱导的急性期反应, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210325/2d9c955949df4b349a439f1a6773499e/b39f4845e869489d95bc545c79cf60fa.jpg, createdBy=303f5433779, createdName=Oranhyg, createdTime=Thu Dec 10 16:37:09 CST 2020, time=2020-12-10, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1678275, encodeId=0fc716e827536, content=<a href='/topic/show?id=12025231333' target=_blank style='color:#2F92EE;'>#急性期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52313, encryptionId=12025231333, topicName=急性期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b8027680692, createdName=feifers, createdTime=Wed May 19 03:26:44 CST 2021, time=2021-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896785, encodeId=80e01896e85cc, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sat May 22 06:26:44 CST 2021, time=2021-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1888249, encodeId=8f10188824927, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Tue Jun 01 22:26:44 CST 2021, time=2021-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915217, encodeId=e5b4191521e2b, content=<a href='/topic/show?id=05343619cf' target=_blank style='color:#2F92EE;'>#Bone#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3619, encryptionId=05343619cf, topicName=Bone)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Fri Jul 02 09:26:44 CST 2021, time=2021-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=909122, encodeId=936c90912245, content=这都能发出来,受教了, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200802/2d1be4b00f2042fdb7133156db033753/68b000cd6c2e409688928b278fd0eebb.jpg, createdBy=4e205263076, createdName=Super骨科赵, createdTime=Fri Dec 18 14:50:17 CST 2020, time=2020-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379696, encodeId=913613e9696be, content=<a href='/topic/show?id=6d8340012ff' target=_blank style='color:#2F92EE;'>#唑来膦酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40012, encryptionId=6d8340012ff, topicName=唑来膦酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3307462, createdName=风铃821, createdTime=Fri Dec 11 14:26:44 CST 2020, time=2020-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=906748, encodeId=34b3906e4882, content=洛索洛芬可抑制唑来膦酸诱导的急性期反应, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210325/2d9c955949df4b349a439f1a6773499e/b39f4845e869489d95bc545c79cf60fa.jpg, createdBy=303f5433779, createdName=Oranhyg, createdTime=Thu Dec 10 16:37:09 CST 2020, time=2020-12-10, status=1, ipAttribution=)]
    2020-12-10 Oranhyg

    洛索洛芬可抑制唑来膦酸诱导的急性期反应

    0

相关资讯

Cell Metab :既能促骨形成又能抑骨吸收,研究发现抗骨质疏松药物新靶标!

在生命过程中,人体的骨组织会伴随着成骨细胞介导的骨形成和破骨细胞介导的骨吸收的进行而不断更新,幼年时新骨形成大于吸收,成年时两者趋于平衡,老年时期则骨吸收明显大于形成,骨质日益疏松。

JCEM:骨质疏松症与帕金森氏病风险的关系

骨质疏松症与PD风险增加有关,尤其是女性。

Eur Respir J:COPD患者使用ICS与骨质疏松和骨折风险的关系

COPD患者发生骨折和骨质疏松症的风险更大,使用大剂量ICS会进一步增加这种风险。

Hematology:去诺舒单抗或可用于治疗骨质疏松症患者的骨质丧失

Noggin是骨形态发生蛋白(BMPs)的拮抗剂,对成骨有很强的作用。骨质疏松症是输血依赖性β-地中海贫血(TDT)的常见并发症,最近地诺单抗成为其一种有希望的治疗选择。本项随机、安慰剂对照

Ann Rheum Dis:银屑病、银屑病关节炎与骨质疏松症之间的关系

综上所述,PsA对骨质疏松的影响是继发性的(例如药物治疗),并不存在因果关系。

Baidu
map
Baidu
map
Baidu
map